Close menu




Defence

Photo credits: pixabay.com

Commented by André Will-Laudien on October 22nd, 2026 | 05:28 CEST

The Chancellor sees the Russian threat! Rearming with Rheinmetall, Hensoldt, Strategic Resources and TKMS

  • Armaments
  • Defence sector
  • Commodities
  • Critical metals
  • Supply chains

Federal Chancellor Friedrich Merz sees measures against the Russian threat as his top priority. Despite widespread concern, many German citizens would have preferred a more economically minded, progressive stance from the CDU. Yet the international defence industry can already celebrate the next upward wave, as the overall situation continues to guarantee robust growth. Finally, a chance to breathe a sigh of relief, as the spark had not really spread to the armaments sector since autumn 2025. But can the charts still be salvaged? Sector leader Rheinmetall has corrected more than 50% from its peak and has already had to backtrack operationally. Nevertheless, CEO Papperger repeatedly steps in as a share buyer, most recently at the end of September near the year's lows. Is this already the turning point? Time for an update on a closely watched sector.

Read

Commented by Jens Castner on October 21st, 2026 | 05:20 CEST

Your Formula for Profits: What Are Bargains PayPal, Citigroup and Almonty Really Worth?

  • Formula
  • Benjamin Graham
  • Value investing
  • Undervaluation
  • Commodities
  • Tungsten
  • Defence
  • Banks
  • Fintech
  • Paypal
  • Citigroup
  • Almonty Industries
  • Fundamental analysis
  • Critical metals
  • Growth

The US stock market is widely considered expensive, and bargains have become increasingly rare. Yet based on 2027 earnings estimates, some stocks still trade at a price-to-earnings (P/E) ratio of 10 or lower. Whether this alone constitutes a buy signal can be assessed using a formula developed by investing legend Benjamin Graham. It requires just a few inputs and accounts for what the P/E ratio alone overlooks: growth. Applied to companies such as PayPal, Citigroup and Almonty Industries, it produces some striking results — including the potential for substantial gains.

Read

Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

  • Tungsten
  • Raw materials
  • Critical raw materials
  • Geopolitics
  • Defence industry
  • Armaments
  • Military
  • Supply chains
  • Investments

The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

Read

Commented by Fabian Lorenz on October 13th, 2026 | 05:36 CEST

Plug Power Losing Hope? Renk Stuck in a Downtrend? RE Royalties Riding the AI Boom!

  • Energy
  • solar energy
  • Wind energy
  • Hydrogen
  • Defence

A look at Renk's share chart brings no joy. Whether over four weeks, six months or 12 months, the share's performance is deep in the red. Analysts recommend buying, but momentum is lacking across the entire defence sector. The latest order does nothing to change that, even if it shows future potential. For AI to realise its full potential, it needs vast amounts of energy. Accordingly, hundreds of billions of US dollars are being invested in energy infrastructure, particularly in North America. This is precisely the market in which RE Royalties operates with an interesting business model. In its latest interview, the company looks to the future with optimism. By contrast, even Plug Power's most optimistic supporters are probably despairing by now.

Read

Commented by Armin Schulz on October 13th, 2026 | 05:26 CEST

Almonty Industries, Rheinmetall, Lockheed Martin – Tungsten, Defence and a Share Price Decline That Could Open Up Opportunities

  • Almonty Industries
  • Rheinmetall
  • Lockheed Martin
  • Tungsten
  • Tungsten Mine
  • Tungsten Concentrate
  • Sangdong
  • Defence
  • Defence Industry

Sangdong is producing tungsten again for the first time since 1993. Almonty's South Korean mine is now supplying a raw material from outside China that is urgently needed in defence and is also found in an increasing number of high-tech devices. China's export restrictions have driven up tungsten prices in the West, while demand remains strong. The same is true of defence. On September 14, Rheinmetall booked an order for tens of thousands of artillery shells, while Lockheed Martin announced a framework agreement worth up to USD 1.2 billion for tactical missiles on September 21. Yet the stock market has so far shown little reaction to these developments. All three stocks are under pressure. We therefore take a closer look at Almonty Industries, Rheinmetall and Lockheed Martin.

Read

Commented by Mario Hose on August 18th, 2022 | 10:28 CEST

Defence Therapeutics CEO Sébastien Plouffe on the next steps in the battle against cancer

  • Expert
  • DefenceTherapeutics
  • Cancer

A publicly traded biotechnology business called Defence Therapeutics is developing new vaccines and antibody-drug conjugates (ADC) products on its own proprietary platform. The ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency. CEO Sébastien Plouffe gives us background on the company's latest development in the battle against cancer.

Read

Commented by Mario Hose on August 2nd, 2022 | 10:57 CEST

Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies

  • Expert
  • Biotech
  • Cancer
  • DefenceTherapeutics

The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.

Read